{"id":1608,"date":"2022-12-25T16:36:29","date_gmt":"2022-12-25T16:36:29","guid":{"rendered":"https:\/\/fonexmedya.com\/?p=1608"},"modified":"2022-12-25T16:36:30","modified_gmt":"2022-12-25T16:36:30","slug":"iki-degerli-guclendiriciler-ne-kadar-etkilidir-cdc-guncellenmis-cekimlerle-ilgili-yeni-gercek-dunya-verilerini-paylasiyor","status":"publish","type":"post","link":"https:\/\/fonexmedya.com\/?p=1608","title":{"rendered":"\u0130ki De\u011ferli G\u00fc\u00e7lendiriciler Ne Kadar Etkilidir? CDC, G\u00fcncellenmi\u015f \u00c7ekimlerle \u0130lgili Yeni Ger\u00e7ek D\u00fcnya Verilerini Payla\u015f\u0131yor"},"content":{"rendered":"

\u0130\u015fte Omicron g\u00fc\u00e7lendiricilerin orijinal COVID a\u015f\u0131lar\u0131na kar\u015f\u0131 nas\u0131l y\u0131\u011f\u0131ld\u0131klar\u0131 hakk\u0131nda bilmeniz gerekenler.<\/h2>\n
\n
\n
    \n
  • Yeni veriler, g\u00fcncellenmi\u015f iki de\u011ferli COVID a\u015f\u0131lar\u0131n\u0131n COVID-19’a kar\u015f\u0131 ek koruma sa\u011flad\u0131\u011f\u0131n\u0131 g\u00f6stermektedir.<\/li>\n
  • G\u00fcncellenmi\u015f g\u00fc\u00e7lendiricilerin art\u0131k mevcut Omikron alt varyantlar\u0131na kar\u015f\u0131 orijinal monovalent a\u015f\u0131dan daha etkili oldu\u011fu d\u00fc\u015f\u00fcn\u00fclmektedir.<\/li>\n
  • G\u00fc\u00e7lendiricilerin, BQ.1 ve BQ.1.1 de dahil olmak \u00fczere yeni ve geli\u015fmekte olan Omicron alt varyantlar\u0131na kar\u015f\u0131 koruma sa\u011flamas\u0131 bekleniyor, ancak uzmanlar s\u00f6ylemek i\u00e7in hen\u00fcz \u00e7ok erken oldu\u011funu s\u00f6yl\u00fcyor.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n

    G\u00fcncellenmi\u015f\u00a0COVID-19\u00a0a\u015f\u0131lar\u0131na ili\u015fkin yeni veriler, iki de\u011ferli g\u00fc\u00e7lendiricilerin orijinal a\u015f\u0131lara k\u0131yasla vir\u00fcs\u00fcn mevcut su\u015flar\u0131na kar\u015f\u0131 daha etkili oldu\u011funu g\u00f6stermektedir.<\/p>\n

    <\/div>\n

    Hastal\u0131k Kontrol ve \u00d6nleme Merkezleri (CDC) ge\u00e7en hafta\u00a0Morbidite ve Mortalite Haftal\u0131k Raporu’nda<\/em>, iki de\u011ferlikli g\u00fc\u00e7lendiricinin “semptomatik SARS-CoV-2 enfeksiyonuna kar\u015f\u0131 \u00f6nemli ek koruma” sa\u011flad\u0131\u011f\u0131na dair ilk ger\u00e7ek d\u00fcnya kan\u0131t\u0131n\u0131 g\u00f6steren bir rapor yay\u0131nlad\u0131.<\/span>1<\/span><\/p>\n

    <\/div>\n

    \u0130ki\u00a0de\u011ferli g\u00fc\u00e7lendiricilerin\u00a0yarar\u0131, bir ki\u015finin son monovalent COVID a\u015f\u0131s\u0131ndan bu yana zamanla artm\u0131\u015ft\u0131r. Etkinlik, iki ila \u00fc\u00e7 ay \u00f6nce orijinal bir a\u015f\u0131 alan 18-49 ya\u015f aras\u0131 \u00e7al\u0131\u015fma kat\u0131l\u0131mc\u0131lar\u0131nda% 30’dan, sekiz veya daha fazla ay \u00f6nce tek de\u011ferli bir COVID a\u015f\u0131s\u0131 alm\u0131\u015flarsa% 56’ya y\u00fckselmi\u015ftir.<\/p>\n

    \n
    <\/div>\n<\/div>\n

    Ger\u00e7ek d\u00fcnyadaki bulgular, hem Pfizer-BioNTech hem de Moderna’n\u0131n Kas\u0131m ay\u0131n\u0131n ba\u015flar\u0131nda iki de\u011ferli g\u00fc\u00e7lendiricileri hakk\u0131nda g\u00fcncellenmi\u015f klinik \u00e7al\u0131\u015fma verilerinin ard\u0131ndan geldi. Her iki \u015firketin de iki de\u011ferlikli g\u00fc\u00e7lendiricileri, benzer g\u00fcvenlik ve tolere edilebilirlik profillerine sahip orijinal COVID-19 a\u015f\u0131lar\u0131na k\u0131yasla \u00f6nemli \u00f6l\u00e7\u00fcde daha y\u00fcksek ba\u011f\u0131\u015f\u0131kl\u0131k tepkileri \u00fcretti.<\/span>2<\/span>3<\/span><\/p>\n

    <\/div>\n

    Veriler bir araya getirildi\u011finde, vir\u00fcse kar\u015f\u0131 s\u00fcrekli koruma i\u00e7in a\u015f\u0131lar konusunda g\u00fcncel kalmak i\u00e7in t\u00fcm uygun ki\u015filerin iki de\u011ferli bir COVID g\u00fc\u00e7lendirici almas\u0131 gerekti\u011fini g\u00f6stermektedir.<\/p>\n

    <\/div>\n
    \u00a0Yeni Omicron Booster Yan Etkileri: \u0130ki De\u011ferli A\u015f\u0131lardan Ne Beklenmeli<\/span><\/div>\n
    <\/div>\n

    Ger\u00e7ek D\u00fcnya Verileri, Klinik \u00c7al\u0131\u015fmalar \u0130ki De\u011ferli A\u015f\u0131 Etkinli\u011fini G\u00f6steriyor<\/span><\/h2>\n

    CDC \u00e7al\u0131\u015fmas\u0131 i\u00e7in ara\u015ft\u0131rmac\u0131lar, yakla\u015f\u0131k 10.000 perakende eczaneden 360.000’den fazla n\u00fckleik asit amplifikasyon testi (NAAT) i\u00e7eren Teste Topluluk Eri\u015fimini Art\u0131rma (ICATT) ulusal SARS-CoV-2 test program\u0131ndan elde edilen verileri kulland\u0131lar. Testler, 14 Eyl\u00fcl-11 Kas\u0131m 2022 tarihleri aras\u0131nda COVID semptomlar\u0131 olan 18 ya\u015f ve \u00fcst\u00fc ki\u015filer aras\u0131nda uyguland\u0131.<\/span>1<\/span><\/p>\n

    <\/div>\n

    \u0130ki de\u011ferli bir g\u00fc\u00e7lendirici dozun g\u00f6receli a\u015f\u0131 etkinli\u011fi – iki daha monovalent a\u015f\u0131 dozuna k\u0131yasla – at\u0131\u015flar aras\u0131ndaki s\u00fcreye ba\u011fl\u0131yd\u0131. \u0130ki ila \u00fc\u00e7 ay \u00f6nce monovalent doz alan 18-49 ya\u015f aras\u0131 insanlar i\u00e7in etkinlik% 30 idi; sekiz veya daha fazla ay \u00f6nce monovalent doz alan ayn\u0131 grup i\u00e7in etkinlik% 56’ya y\u00fckseldi.<\/p>\n

    <\/div>\n

    Ya\u015f artt\u0131k\u00e7a g\u00f6receli a\u015f\u0131 etkinli\u011fi de biraz azalm\u0131\u015ft\u0131r: 50-64 ya\u015f aras\u0131 insanlar aras\u0131nda, iki de\u011ferli a\u015f\u0131lar, son monovalent at\u0131\u015ftan bu yana ge\u00e7en s\u00fcreye ba\u011fl\u0131 olarak% 31 ve% 48 etkiliydi; 65 ya\u015f ve \u00fcst\u00fc insanlar aras\u0131nda% 28 ve% 43 etkiliydi.<\/p>\n

    <\/div>\n

    CDC \u00e7al\u0131\u015fmas\u0131ndan \u00f6nce, hem Moderna hem de Pfizer-BioNTech, g\u00fcncellenmi\u015f COVID a\u015f\u0131lar\u0131ndan yeni klinik deneme verilerini payla\u015ft\u0131. \u015eirket veri setleri, g\u00fc\u00e7lendiricilerin COVID vakalar\u0131n\u0131 veya ciddi hastal\u0131klar\u0131 \u00f6nleme yeteneklerine bakmamas\u0131na ra\u011fmen, vir\u00fcslerle sava\u015fan ba\u011f\u0131\u015f\u0131kl\u0131k sisteminin bile\u015fenlerinden biri olan antikorlar\u0131n laboratuvar \u00f6l\u00e7\u00fcmlerine ve SARS-CoV-2 vir\u00fcs\u00fcn\u00fc n\u00f6tralize etme yeteneklerine bak\u0131yorlar.<\/p>\n

    <\/div>\n

    Johns Hopkins Bloomberg Halk Sa\u011fl\u0131\u011f\u0131 Okulu’nda uluslararas\u0131 sa\u011fl\u0131k do\u00e7enti ve a\u015f\u0131 uzman\u0131\u00a0olan Kawsar Talaat’a\u00a0g\u00f6re, antikor verileri tipik olarak bir a\u015f\u0131n\u0131n ger\u00e7ek d\u00fcnyada ne kadar iyi sonu\u00e7 verece\u011finin olduk\u00e7a iyi bir g\u00f6stergesidir.<\/p>\n

    <\/div>\n

    Dr. Talaat, “Ge\u00e7mi\u015fte g\u00f6rd\u00fc\u011f\u00fcm\u00fcz \u015fey, etkinlik verilerini antikor verileriyle kar\u015f\u0131la\u015ft\u0131rd\u0131\u011f\u0131m\u0131zda, antikor verilerinin insanlar\u0131n ne kadar iyi korundu\u011funu tahmin etme e\u011filiminde oldu\u011fudur” dedi.<\/span><\/p>\n

    <\/div>\n

    Pfizer’den yap\u0131lan bir bas\u0131n a\u00e7\u0131klamas\u0131nda \u015firket, g\u00fc\u00e7lendiricisinin, ayn\u0131 ya\u015f grubundaki orijinal COVID a\u015f\u0131lar\u0131na k\u0131yasla, 55 ya\u015f\u0131ndan b\u00fcy\u00fck ki\u015filerde BA.4 ve BA.5 Omicron varyantlar\u0131na kar\u015f\u0131 antikorlar\u0131 4 kat art\u0131rd\u0131\u011f\u0131n\u0131 bildirdi. \u0130ki de\u011ferli a\u015f\u0131n\u0131n g\u00fc\u00e7lendirici dozunu ald\u0131ktan bir ay sonra, antikorlar 55 ya\u015f\u0131ndan b\u00fcy\u00fck yeti\u015fkinlerde 13.2 kat, 18 ila 55 ya\u015f aras\u0131 yeti\u015fkinlerde 9.5 kat artt\u0131. Bu, orijinal a\u015f\u0131 ile sadece 2.9 kat kar\u015f\u0131la\u015ft\u0131r\u0131l\u0131r.<\/p>\n

    <\/div>\n

    Moderna’n\u0131n\u00a0verileri, t\u00fcm kat\u0131l\u0131mc\u0131lar aras\u0131nda 18 ila 65 ya\u015flar\u0131 aras\u0131nda de\u011fi\u015fen tutarl\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k tepkileri g\u00f6sterdi. Bir bas\u0131n a\u00e7\u0131klamas\u0131nda \u015firket, \u00f6n g\u00fc\u00e7lendirici seviyelere k\u0131yasla antikorlarda ortalama 15.1 kat art\u0131\u015f oldu\u011funu bildirdi. G\u00fc\u00e7lendiriciyi almadan \u00f6nce daha \u00f6nce COVID enfeksiyonu ge\u00e7irmi\u015f olanlarda, antikor seviyeleri 26.4 kat artt\u0131; Daha \u00f6nce enfeksiyonu olmayanlar i\u00e7in, antikorlar 9.8 kat artt\u0131.<\/p>\n

    <\/div>\n
    \u00a0Omicron G\u00fc\u00e7lendiriciler Bu K\u0131\u015f 90.000 Hayat Kurtarabilir – Ama Sadece \u0130nsanlar Onlar\u0131 Al\u0131rsa<\/span><\/div>\n
    <\/div>\n

    \u0130ki De\u011ferli G\u00fc\u00e7lendiricilerin Gelecekteki Varyantlara Kar\u015f\u0131 Etkinli\u011fi<\/span><\/h2>\n

    En son\u00a0CDC verilerine\u00a0g\u00f6re, yeni Omicron alt varyantlar\u0131 – \u00f6zellikle BQ.1 ve BQ.1.1 – iki de\u011ferli g\u00fc\u00e7lendiricilerin uyarland\u0131\u011f\u0131 BA.4 ve BA.5 alt varyantlar\u0131n\u0131 ge\u00e7iyor.<\/span>1<\/span><\/p>\n

    <\/div>\n

    Cleveland Clinic’te bula\u015f\u0131c\u0131 bir hastal\u0131k doktoru olan\u00a0Sherif Mossad’a\u00a0g\u00f6re, yeni g\u00fc\u00e7lendiricilerin daha yayg\u0131n hale gelene kadar yeni veya gelecekteki varyantlara kar\u015f\u0131 ne kadar etkili oldu\u011funu anlayamayaca\u011f\u0131z.<\/p>\n

    <\/div>\n

    Ancak g\u00fcncellenmi\u015f g\u00fc\u00e7lendiriciler, monovalent a\u015f\u0131ya k\u0131yasla daha geni\u015f bir koruma aral\u0131\u011f\u0131na sahip,\u00a0Jennifer Bourgeois, SingleCare’de eczac\u0131 uzman\u0131 olan PharmD,\u00a0Health’e<\/em>\u00a0verdi\u011fi deme\u00e7te. \u0130ki de\u011ferli a\u015f\u0131, hem Omicron varyantlar\u0131ndan hem de SARS-CoV-2’nin orijinal su\u015fundan hedefler i\u00e7erir. Daha fazla hedefe sahip olarak, iki de\u011ferli a\u015f\u0131n\u0131n gelecekteki varyantlara kar\u015f\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k tepkisi ortaya \u00e7\u0131karabilmesi i\u00e7in daha fazla \u015fans vard\u0131r.<\/p>\n

    <\/div>\n

    \u015eirketin bas\u0131n a\u00e7\u0131klamas\u0131nda, Moderna \u0130cra Kurulu Ba\u015fkan\u0131 St\u00e9phane Bancel ayr\u0131ca, verilerin iki de\u011ferli a\u015f\u0131n\u0131n \u00f6zellikle BQ.1.1’e kar\u015f\u0131 bir miktar koruma sa\u011flad\u0131\u011f\u0131n\u0131 g\u00f6sterdi\u011fini s\u00f6yledi.<\/p>\n

    <\/div>\n

    Bancel, “\u0130ki de\u011ferlikli g\u00fc\u00e7lendiricilerimiz ayr\u0131ca, ara\u015ft\u0131rma tahlillerinde, giderek daha bask\u0131n bir \u015fekilde ortaya \u00e7\u0131kan bir varyant olan BQ.1.1’e kar\u015f\u0131 n\u00f6tralize edici aktiviteyi g\u00f6steriyor” dedi Bancel, “g\u00fcncellenmi\u015f a\u015f\u0131lar\u0131n, vir\u00fcs ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131m\u0131zdan ka\u00e7mak i\u00e7in h\u0131zla geli\u015fmeye devam ettik\u00e7e koruma sa\u011flama potansiyeline sahip oldu\u011funu do\u011frulad\u0131.”<\/p>\n

    <\/div>\n

    Dr. Talat ayr\u0131ca, g\u00fcncellenmi\u015f g\u00fc\u00e7lendiricilerin yeni ve ortaya \u00e7\u0131kan Omicron alt varyantlar\u0131na kar\u015f\u0131 etkinli\u011fi koruyaca\u011f\u0131ndan umutlu, ancak sadece zaman\u0131n kesin olarak s\u00f6yleyece\u011fini savunuyor.<\/p>\n

    <\/div>\n

    Dr. Talaat, “Ayn\u0131 ba\u015fak proteinine sahipler, bu da ayn\u0131 a\u015f\u0131 hedef alanlar\u0131na sahip olduklar\u0131 anlam\u0131na geliyor, bu y\u00fczden a\u015f\u0131n\u0131n bunlara kar\u015f\u0131 da \u00e7al\u0131\u015fmas\u0131 bekleniyor” dedi. “Ama \u00f6n\u00fcm\u00fczdeki \u00fc\u00e7 ila alt\u0131 ay i\u00e7inde ne olacak, s\u00f6ylemek i\u00e7in \u00e7ok erken.”<\/span><\/p>\n

    <\/div>\n
    \u00a0Yeni COVID Varyantlar\u0131 K\u0131\u015f Dalgas\u0131n\u0131 Tetikleyebilir – BQ.1, XBB ve Di\u011ferleri Hakk\u0131nda Bilinmesi Gerekenler<\/span><\/div>\n
    <\/div>\n

    G\u00fcncellenmi\u015f G\u00fc\u00e7lendiriciyi Almay\u0131 Geciktirmeyin<\/span><\/h2>\n

    Yeni iki de\u011ferli a\u015f\u0131y\u0131 hen\u00fcz almad\u0131ysan\u0131z, Bourgeois bunu m\u00fcmk\u00fcn olan en k\u0131sa s\u00fcrede yapman\u0131z\u0131 \u00f6nerir.<\/p>\n

    <\/div>\n

    Bourgeois, “T\u00fcm yeti\u015fkinlere, \u00f6zellikle de 65 ya\u015f ve \u00fcst\u00fc olanlara ve altta yatan sa\u011fl\u0131k ko\u015fullar\u0131na sahip herkese, g\u00fcncellenmi\u015f g\u00fc\u00e7lendirici olan mevcut en geni\u015f a\u015f\u0131 ile kendilerini korumalar\u0131n\u0131 \u00f6neriyorum” dedi.<\/p>\n

    <\/div>\n

    Dr. Talat, yakla\u015fan tatil sezonunun, aile toplant\u0131lar\u0131 ba\u015flad\u0131\u011f\u0131nda y\u00fcksek antikor seviyelerine sahip olmak i\u00e7in er ya da ge\u00e7 takviye edilmek i\u00e7in iyi bir neden oldu\u011funu s\u00f6yledi.<\/p>\n

    <\/div>\n

    G\u00fcncellenmi\u015f g\u00fc\u00e7lendiriciler ve bu konuda \u00e7o\u011fu a\u015f\u0131 ile ak\u0131lda tutulmas\u0131 gereken bir \u015fey, enfeksiyona kar\u015f\u0131 tam olarak koruma sa\u011flayamayacaklar\u0131, ancak ciddi hastal\u0131klara, hastaneye yat\u0131\u015flara ve \u00f6l\u00fcme kar\u015f\u0131 koruyacaklar\u0131d\u0131r.<\/p>\n

    <\/div>\n

    Dr. Talaat, “M\u00fckemmel de\u011fil, g\u00fc\u00e7lenebilir ve yine de COVID’e yakalanabilirsiniz” dedi. “\u0130lk a\u015f\u0131lardan elde edilen orijinal verileri g\u00f6rd\u00fc\u011f\u00fcm\u00fczde, enfeksiyona kar\u015f\u0131 koruma i\u00e7in test etmedik, semptomatik hastal\u0131k i\u00e7in test ettik ve buna kar\u015f\u0131 \u00e7ok iyi korudular. Ancak ger\u00e7ek \u015fu ki, enfeksiyonu ve solunum yolu hastal\u0131klar\u0131n\u0131n bula\u015fmas\u0131n\u0131 \u00f6nlemede hi\u00e7bir zaman \u00e7ok iyi olmad\u0131k. “<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

    \u0130\u015fte Omicron g\u00fc\u00e7lendiricilerin orijinal COVID a\u015f\u0131lar\u0131na kar\u015f\u0131 nas\u0131l y\u0131\u011f\u0131ld\u0131klar\u0131 hakk\u0131nda bilmeniz gerekenler. Yeni veriler, g\u00fcncellenmi\u015f iki de\u011ferli COVID a\u015f\u0131lar\u0131n\u0131n COVID-19’a kar\u015f\u0131 ek koruma sa\u011flad\u0131\u011f\u0131n\u0131 g\u00f6stermektedir. G\u00fcncellenmi\u015f g\u00fc\u00e7lendiricilerin art\u0131k mevcut Omikron alt varyantlar\u0131na kar\u015f\u0131 orijinal monovalent a\u015f\u0131dan daha etkili oldu\u011fu d\u00fc\u015f\u00fcn\u00fclmektedir. G\u00fc\u00e7lendiricilerin, BQ.1 ve BQ.1.1 de dahil olmak \u00fczere yeni ve geli\u015fmekte olan Omicron alt varyantlar\u0131na …<\/p>\n","protected":false},"author":1,"featured_media":1609,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[240],"tags":[],"class_list":["post-1608","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-tir-saglik"],"_links":{"self":[{"href":"https:\/\/fonexmedya.com\/index.php?rest_route=\/wp\/v2\/posts\/1608","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fonexmedya.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fonexmedya.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fonexmedya.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/fonexmedya.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1608"}],"version-history":[{"count":1,"href":"https:\/\/fonexmedya.com\/index.php?rest_route=\/wp\/v2\/posts\/1608\/revisions"}],"predecessor-version":[{"id":1610,"href":"https:\/\/fonexmedya.com\/index.php?rest_route=\/wp\/v2\/posts\/1608\/revisions\/1610"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fonexmedya.com\/index.php?rest_route=\/wp\/v2\/media\/1609"}],"wp:attachment":[{"href":"https:\/\/fonexmedya.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1608"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fonexmedya.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1608"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fonexmedya.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1608"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}